Janney Montgomery Scott LLC Takes Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Janney Montgomery Scott LLC acquired a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBUGet Rating) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,793 shares of the company’s stock, valued at approximately $107,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its stake in shares of Caribou Biosciences by 168.4% during the first quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company’s stock valued at $36,000 after acquiring an additional 2,475 shares during the last quarter. Amalgamated Bank bought a new position in Caribou Biosciences in the first quarter worth about $45,000. Penserra Capital Management LLC bought a new position in Caribou Biosciences in the first quarter worth about $61,000. Invesco Ltd. bought a new position in Caribou Biosciences in the first quarter worth about $110,000. Finally, Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Caribou Biosciences during the second quarter valued at approximately $70,000. 64.73% of the stock is owned by institutional investors.

Insider Transactions at Caribou Biosciences

In other news, insider Steven Kanner sold 43,248 shares of Caribou Biosciences stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $11.22, for a total transaction of $485,242.56. Following the transaction, the insider now owns 302,059 shares in the company, valued at approximately $3,389,101.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Caribou Biosciences news, insider Steven Kanner sold 43,248 shares of Caribou Biosciences stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $11.22, for a total value of $485,242.56. Following the sale, the insider now directly owns 302,059 shares in the company, valued at approximately $3,389,101.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Ryan Fischesser sold 10,000 shares of Caribou Biosciences stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $10.80, for a total transaction of $108,000.00. Following the completion of the sale, the vice president now owns 110,366 shares in the company, valued at $1,191,952.80. The disclosure for this sale can be found here. Corporate insiders own 8.50% of the company’s stock.

Analyst Ratings Changes

CRBU has been the subject of a number of analyst reports. Citigroup decreased their target price on shares of Caribou Biosciences from $39.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, August 29th. HC Wainwright decreased their target price on shares of Caribou Biosciences from $28.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, August 18th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences currently has a consensus rating of “Buy” and an average target price of $29.33.

Caribou Biosciences Trading Down 1.1 %

Shares of CRBU stock opened at $9.08 on Friday. Caribou Biosciences, Inc. has a 12-month low of $4.89 and a 12-month high of $22.80. The firm’s 50 day moving average is $10.22 and its 200 day moving average is $8.79. The stock has a market capitalization of $553.90 million, a P/E ratio of -6.08 and a beta of 1.81.

Caribou Biosciences Company Profile

(Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Featured Articles

Institutional Ownership by Quarter for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.